Independent assessment of lenvatinib plus everolimus in patients with metastatic renal cell carcinoma

Lancet Oncol. 2016 Jan;17(1):e4-5. doi: 10.1016/S1470-2045(15)00543-4. Epub 2015 Dec 23.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Comparative Study
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Carcinoma, Renal Cell / diagnostic imaging*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / secondary
  • Disease-Free Survival
  • Everolimus / administration & dosage
  • Female
  • Humans
  • Kidney Neoplasms / diagnostic imaging*
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / pathology
  • Magnetic Resonance Imaging
  • Male
  • Phenylurea Compounds / administration & dosage
  • Quinolines / administration & dosage
  • Response Evaluation Criteria in Solid Tumors
  • Retrospective Studies
  • Single-Blind Method
  • Tomography, X-Ray Computed

Substances

  • Phenylurea Compounds
  • Quinolines
  • Everolimus
  • lenvatinib